RGNX News

Gene Therapies in Ophthalmology Market Competitive Landscape Report 2026: Comprehensive Insights About 55+ Companies and 125+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Kyndryl Holdings, Inc. (KD), uniQure N.V. (QURE), and REGENXBIO Inc. (RGNX) Announced by Holzer & Holzer, LLC

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of REGENXBIO Inc. to Contact the Firm Today!

Pomerantz LLP Notifies Investors of Class Action Filing Against REGENXBIO Inc. – RGNX

Class Action Lawsuit Reminder from Pomerantz LLP for Investors of REGENXBIO Inc. – RGNX

RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Lifshitz Law PLLC Announces Investigations of REGENXBIO Inc. (NASDAQ: RGNX), Kyndryl Holdings, Inc. (NYSE: KD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX